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1 ABSTRACT  
Interest in the role of bioactive compounds present in plants has increased 
dramatically over the last decade. Many compounds have been discovered and 
intensively studied to evaluate their effects on health. Phenolic compounds, 
specifically lignan phytoestrogens, have received particular attention.  
Enterolactone, the most abundant lignan in humans, is produced by intestinal 
microflora from dietary precursors found widely in plants. Enterolactone has been 
proposed to possess a broad spectrum of biological properties, giving it the potential 
to reduce risk of chronic diseases. Epidemiological evidence is, however, sparse and 
contradictory.  
The aim of this study was to define the distribution of serum enterolactone 
concentration among Finnish adults and to examine its determinants, including 
selected background characteristics, dietary factors, and use of antimicrobials. 
Moreover, the association between serum enterolactone concentration and the risk of 
breast and prostate cancers was assessed. 
Serum enterolactone concentration was analyzed among participants of the 
FINDIET survey carried out as part of the cross-sectional FINRISK survey in 1997. 
The range in serum enterolactone concentration was large (0-183 nmol/l), but 90% 
of subjects had a concentration under 38 nmol/l. The mean serum enterolactone 
concentration (nmol/l) of men and women was 16.9 (SD 13.8, median 13.4) and 
19.6 (SD 16.8, median 15.6), respectively. 
Serum enterolactone concentration was negatively associated with the use of 
antimicrobials and positively associated with self-reported constipation in both 
genders. In addition, it had a negative association with smoking and body mass 
index and a positive association with age in women, and a positive association with 
the length of time from last antimicrobial treatment in men. The mean daily lignan 
intake was low, <0.2 mg, and serum enterolactone concentration rather weakly 
reflected the intake of lignans but more strongly the consumption of lignan-
containing foods, i.e. fruit, berries, and vegetables.  
To examine the association between serum enterolactone concentration and risk of 
breast cancer, enterolactone concentrations were measured in serum collected in four 
independent cross-sectional FINRISK surveys (1982-1997) from 206 women with 
breast cancer diagnosed during follow-up (mean 8.0 years) and from 215 controls 
frequency-matched by study cohort, 5-year age group, and study area. The mean 
serum enterolactone concentration (nmol/l) did not differ between cases and 
14 
controls, 25.2 (SD 22.2) vs. 24.0 (SD 21.3) and no association was found between 
serum enterolactone concentration and risk of breast cancer (OR for the highest vs. 
the lowest quartile 1.30, 95% CI 0.73-2.31). 
The association between serum enterolactone concentration and risk of prostate 
cancer was assessed among participants of the Alpha-Tocopherol, Beta-Carotene 
Cancer Prevention Study. Enterolactone concentrations were measured in serum 
collected at trial baseline from 214 men with prostate cancer diagnosed during 
follow-up (median 6 years) and from 214 controls matched by age, date of baseline 
blood collection, intervention group, and local study area. No difference was present 
in mean serum enterolactone concentration (nmol/l) between cases and controls, 
15.9 (SD 15.2) vs. 16.9 (SD 14.9) and no association was found between serum 
enterolactone concentration and risk of prostate cancer (OR for the highest vs. the 
lowest quartile 0.71, 95% CI 0.42-1.21). 
In conclusion, a large range in serum enterolactone concentration (0-183 nmol/l) 
was observed, but 90% of subjects had a concentration under 38 nmol/l. Use of 
antimicrobials and self-reported constipation were the most important determinants 
of serum enterolactone concentration, supporting a central role of the gut 
environment in the bioavailability of lignans. Serum enterolactone concentration 
was not protectively associated with the risk of breast or prostate cancer. 
15 
2 INTRODUCTION 
The great interest over the last several decades in diet and human cancer derives 
from the large variation present in rates of specific cancers among different 
populations of the world (Parkin et al. 1999, Pisani et al. 1999, Hsing et al. 2000). 
The highest rates of breast and prostate cancers have been observed in Western 
societies, where diets are typically high in fat and low in vegetables, while rates 
have been lower in Asian populations and developing countries, where mainly plant-
based diets are consumed. Rates are, however, also increasing in developing 
countries, and offspring of migrants moving from countries with low breast and 
prostate cancer incidence to areas with a higher incidence adopt the rates of the new 
environment (Shimizu et al. 1991, Ziegler et al. 1993). This indicates that the 
differences in cancer rates are largely attributable to environmental and lifestyle 
factors rather than to genetics. Diet is a prominent environmental factor estimated to 
attribute to about one-third of cancer deaths (Doll & Peto 1981). In contrast to many 
other risk factors of cancer, diet is modifiable and therefore an area of much interest, 
both scientifically and among the public at large. 
Of particular interest is the class of dietary compounds known as phytoestrogens. 
Based on their chemical structure, phytoestrogens are divided into three main 
classes, lignans, isoflavonoids, and coumestans. Almost any plant food may contain 
phytoestrogens, although the amounts and combinations of different compounds 
vary (Thompson et al. 1991, Mazur 1998, Liggins et al. 2000). The main dietary 
sources of isoflavonoids and coumestans are soybeans, and alfalfa sprouts and 
beans, respectively. Lignans are more widely distributed in plants, found, for 
example, in whole grains, berries, and seeds, and are therefore probably the most 
important phytoestrogens in Western populations, including Finland. Hence, lignans 
and their most abundant human metabolite, enterolactone, are the focus of this 
study. 
Enterolactone, which is produced by intestinal microflora from dietary precursors, 
has been proposed to possess several biological activities (Adlercreutz 2002, Wang 
2002), including but not limited to antioxidant activity and inhibition of several 
enzymes involved in steroid hormone metabolism, thus providing potential 
mechanisms for a preventive influence in hormone-dependent cancers and 
cardiovascular diseases. Epidemiological evidence is, however, limited and 
inconclusive. Some epidemiologic studies have reported protective associations 
between enterolactone exposure and chronic diseases (Ingram et al. 1997, 
Vanharanta et al. 1999, Pietinen et al. 2001, Dai et al. 2002), while other studies 
have not found these associations (den Tonkelaar et al. 2001, Stattin et al. 2002, 
16 
Peeters et al. 2003). The present work extends previous research by examining 
serum enterolactone concentration and its determinants in a large population sample. 
The associations between serum enterolactone concentration and breast and prostate 
cancers have also been assessed in two prospective design studies. 
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3 REVIEW OF THE LITERATURE 
3.1 Dietary lignans 
3.1.1 Origin and classification 
Lignans are a large group of secondary plant metabolites found throughout the plant 
kingdom (Howarth 1936, Ayres & Loike 1990). They typically possess a 
dibenzylbutane structure, which is formed by the dimerization of two cinnamic acid 
residues (Figure 1). Nearly five hundred natural lignans have been identified in 
plants and plant parts (stems, leaves, seeds, fruits) (Ayres & Loike 1990, Ward 
1993). 
Figure 1. Basic structure of lignans. 
 
 
 
 
Due to the structural diversity of lignans, their chemical classification and 
nomenclature has been challenging (Ayres & Loike 1990). In medical literature, 
lignans have typically been divided into plant lignans and mammalian lignans, also 
called enterolignans, which are formed from plant lignans by the intestinal 
microflora. Here, were focus on the mammalian lignan enterolactone, but another 
mammalian lignan, enterodiol, as well as dietary precursors for both, mainly 
matairesinol and secoisolariciresinol, will also be discussed. 
3.1.2 Food sources 
Secoisolariciresinol and matairesinol are considered to be the major precursors of 
mammalian lignans. These precursors are widely distributed in the plant kingdom, 
especially in fiber-rich foods (Mazur 1998, Liggins et al. 2000). The richest source 
of lignans is flaxseed, but they are also found in other seeds, whole grain cereals, 
and various vegetables, fruit, and berries. Some examples of lignan content of foods 
have been collected in Table 1. The values are given per dry weight, and therefore, 
 
                      A dimer of cinnamic acid 
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many fruits and vegetables that have high water content may give the impression 
that they are richer sources of lignans than they actually are. 
Apart from the above precursors, pinoresinol, lariciresinol, syringaresinol, 
isolariciresinoland, artigenin, and hydroxymatairesinol have recently also been 
identified as precursors of mammalian lignans (Saarinen et al. 2000, Wang et al. 
2000, Heinonen et al. 2001). The first three are present in cereals (Heinonen et al. 
2001). Only a few preliminary analytical results have thus far been published. 
3.1.3 Intake 
Current information about typical dietary intake of lignans is limited (Table 2). Most 
of the studies have been carried out in the United States and a wide range in daily 
lignan intake, from 100 µg in women from California (Horn-Ross et al. 2002a, 
2002b) to over 1 300 µg in men from Texas (Walcott et al. 2002), has been reported. 
The main sources of lignans are cereal products, fruit and berries, vegetables, coffee 
and tea, and alcoholic beverages. However, caution must be taken when comparing 
these reports because of differences in collection of food consumption data and 
development of phytoestrogen databases. 
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Table 1. Lignan content of selected foods (µg/100g dry weight). 
 
 
SECO MAT 
 
 SECO MAT 
  
SECO MAT 
Legumes    Nuts and seeds    Berries and fruits   
Kidney bean1,2 56-153 Tr  Almond4 107 Tr  Apple5 Tr 0 
Lentil3 0-7 Tr  Cashew nut4 257 4  Avocado5 77 16 
Pea3 3-13 Tr  Flaxseed5 369 900 1087  Banana4 10 0 
Soybean3  13-273 Tr  Hazelnut4 119 4  Blueberry4 835 0 
    Peanut1,2 298-333 Tr  Black currant4 388 10 
Vegetables    Pistachio nut4 96 0  Bramble5 3718 23 
Beetroot4 100 Tr  Poppy seed2 14 12  Cantaloupe5 184 0 
Broccoli2 414 23  Sesame seed4 90 608  Cloudberry4 203 0 
Cabbage4 33 Tr  Sunflower seed5 610 0  Cranberry1,2 1054-1510 0 
Carrot1,2 192-370 Tr-3  Walnut4 163 5  Lemon5 61 0 
Cauliflower4 97 Tr      Lingonberry4 1510 0 
Chives5 1254 Tr  Grains and cereals    Orange5 77 0 
Cucumber5 25 Tr  Barley (whole grain)2 58 0  Papaya5 8 0 
Eggplant5 100 3  Barley bran2 63 0  Plum4 5 0 
Garlic1,2 379-380 Tr-4  Crisp bread6 28-42 42-62  Raspberry4 139 0 
Mushroom2 8 0  Maize5 16 0  Red currant4 165 0 
Onion4 83 8  Oat bran2 24 155  Strawberry1,2 1205-1500 5-78 
Paprika, pepper4 117 7  Oat meal2 13 0     
Potato (peeled) 4 10 6  Rice5  16 Tr  Beverages   
Pumpkin4 3870 4  Rye (whole grain)2 47 65  Black tea (brewed)4 1050-2418 90-305 
Radish5  33 3  Rye bran2 132 167  Green tea (brewed)4 1794-2887 195-277 
Red cabbage4 141 Tr  Wheat (whole grain)2 33 3  Red wine5  686-1280 74-98 
Tomato5 52 7  Wheat bran2 110 0  White wine5 136-174 17-22 
Zucchini4 817 Tr  Wheat white meal2 8 0     
           
MAT = matairesinol, SECO = secoisolarisiresinol, Tr = traces 
1Mazur & Adlercreutz 2000, 2Adlercreutz & Mazur 1997, 3Mazur et al. 1998, 4Mazur & Adlercreutz 1998, 5Mazur 1998, 6Mazur et al. 1996 
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Table 2. Dietary intake of plant lignans (µg/day) based on the food frequency questionnaire in selected populations.  
Country Population Age (years)                      Median intake of lignans                        Sources Reference  
Germany 666 F1 <50 MAT + SECO 563 Nut and seeds, bread, wine, onion/garlic Linseisen et al. 2004 
The Netherlands 17 140 F 50-69 MAT 80 ± 502, SECO 1030 ± 42 Grain products, fruit, vegetables, 
coffee/tea, alcoholic beverages 
Boker et al. 2002 
USA  107 M1 60.6 ± 6.93 MAT 46, SECO 483 Black tea, flaxseed bread, cranberry 
juice/cranberries 
Strom et al. 1999 
USA 447 F  50-79 MAT 364, SECO 1394 Orange juice, coffee, sweet potatoes, rice, 
peaches, apricots 
Horn-Ross et al. 2000 
USA 1610 F1 35-79 MAT ~305, SECO ~1225 Not reported Horn-Ross et al. 2001 
USA 964 F Postmenopausal MAT 23 ± 192, SECO 622 ± 3572 Fruit (no citrus), grain  products, berries de Kleijn et al. 2001 
USA 558 F1 20-74 MAT ~345, SECO ~705 Not reported Horn-Ross et al. 2002a 
USA 111 526 F 21-103 MAT 234, SECO 854 Not reported Horn-Ross et al. 2002b 
USA 136 M1 18-55 MAT + SECO ~13555,6 Black tea, cranberry juice  Walcott et al. 2002 
USA 470 F1 35-79 MAT 30, SECO 138 Not reported  Horn-Ross et al. 2003 
M = male, F = female, MAT = matairesinol, SECO = secoisolarisiresinol 
1Controls 
2Mean ± SD  
3Mean ± SE 
4Mean 
5Values are rough estimates based on distributions presented by the author 
6Median lignan intake in µg/d has been estimated from median energy (1941 kcal) and lignan intake (698 µg/1000 kcal) intake
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3.2 Lignans in humans  
3.2.1 Metabolism 
Some twenty years ago, two research groups independently characterized and 
reported the presence of enterolactone in human urine (Setchell et al. 1980, Stitch et 
al. 1980). It was initially assumed to be a steroidal compound of ovarian origin due 
to enterolactone excretion following a menstrual cycle and occurring in relatively 
large quantities during early pregnancy (Stitch et al. 1980). Soon afterwards, 
enterolactone (and enterodiol) was demonstrated to be a metabolic compound of the 
gut microflora (Axelson et al. 1982). 
The best-known precursors of mammalian lignans, secoisolariciresinol and 
matairesinol, occur in plants as glycosidic conjugates which are hydrolyzed and 
further converted to mammalian lignans in the gut (Setchell et al. 1981a, 1981b, 
Axelson et al. 1982, Borriello et al. 1985). Secoisolariciresinol is transformed to 
enterodiol through reactions involving demethylation and dehydroxylation (Figure 
2). Enterodiol can be further oxidized to enterolactone. Matairesinol is converted to 
enterolactone through demethylation and dehydroxylation.  
After absorption, mammalian lignans are conjugated mainly with glucuronic acid 
and to a lesser degree with sulfates in the liver (Setchell et al. 1981a, 1981b, 
Axelson et al. 1982, Borriello et al. 1985). Like endogenous estrogens, lignans are 
located in the enterohepatic circulation and are excreted mainly in the urine but also 
in the feces (Axelson & Setchell 1981, Pettersson et al. 1996). 
Studies in germ-free rats (Bowey et al. 2003), in humans administered antibiotics 
(Setchell et al. 1981a), and in ileostomy patients (Pettersson et al. 1996) have 
confirmed that production of mammalian lignans depends on the bacteria in the 
intestinal tract. However, bacterial strains responsible for the conversion of plant 
lignans to mammalian lignans have not been fully identified. In vitro studies have 
demonstrated that metabolism of lignans occurs under both anaerobic and aerobic 
conditions, indicating action by facultative bacteria (Borriello et al. 1985). Clostridia 
were suggested to be involved in the conversion (Setchell et al. 1981a), but this 
hypothesis is not supported by more recent studies (Borriello et al. 1985). 
Peptococcus and eubacterium strains have also been suggested to be involved in the 
metabolism of lignans (Wang et al. 2000). Although the conversion of plant lignans 
to mammalian lignans is thought to be efficient, detection of secoisolariciresinol and 
matairesinol in the urine (Bannwart et al. 1989) indicates that they may also be 
absorbed in unchanged form from the gastrointestinal tract. 
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Figure 2. Metabolism of plant lignans to mammalian lignans. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2.2 Bioavailability and pharmacokinetics 
Limited studies with a small number of subjects and of brief duration - blood 
samples not collected beyond 24 h - have assessed the bioavailability and 
pharmacokinetic profile of lignans in human subjects. In these studies, no increase in 
plasma enterolactone concentration was observed until 8-9 h after lignan 
supplementation (Morton et al. 1997b, Nesbitt et al. 1999, Mazur et al. 2000), 
probably due to enterolactone being produced by gut microflora. The increase in 
enterolactone concentration continued up to 24 h in serum (Morton et al. 1997b, 
Mazur et al. 2000) and up to 35-36 h in urine (Mazur et al. 2000), although 
substantial variation was present in these timeframes as well as in the maximal 
levels achieved among participants. Variation in the recovery of plant lignans 
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determined as urinary mammalian lignans was also high, from –23% to 438% 
(Mazur et al. 2000).  
No human studies have been performed to assess mammalian lignan disposition 
after supplementation, but in rats the highest levels were measured in tissues 
involved in lignan metabolism, i.e. intestinal, hepatic, and renal as well as certain 
estrogen-sensitive tissues, such as the uterus, but not the mammary gland (Rickard 
& Thompson 1998). 
3.2.3 Concentrations in serum and urine 
Table 3 presents information on plasma and serum concentrations of lignans in 
various populations. Mean plasma and serum lignan concentrations appear to be in 
the range of 6.6–191 nmol/l in individuals consuming typical diets; the highest 
levels were observed in postmenopausal women in Israel (Brzezinski et al. 1997) 
and the lowest in middle-aged Norwegian men (Stattin et al. 2002).  
As with plasma levels, wide ranges in urinary lignans – from 3.4 µmol/24-h to  
1850 µmol/24-h – have been observed (Table 3). However, caution must be taken 
when comparing these reports because of differences in specimen collection and the 
presentation of results. 
Correlations between serum and urinary enterolactone measurements have been 
shown to vary from 0.84 (Valentin-Blasini et al. 2003) to 0.91 (Stumpf & 
Adlercreutz 2003). For enterodiol, a somewhat lower correlation (0.62) has been 
found (Valentin-Blasini et al. 2003). 
In addition to urine, plasma, and serum, lignans have been detected in other biologic 
specimens, including amniotic fluid (Adlercreutz et al. 1999), cord plasma 
(Adlercreutz et al. 1999), feces (Adlercreutz et al. 1995), nipple aspirate fluid 
(Hargreaves et al. 1999), prostatic fluid (Morton et al. 1997a), saliva (Finlay et al. 
1991), semen (Dehennin et al. 1982), and certain tissues, e.g. prostate tissue (Hong 
et al. 2002). Information on tissue concentrations is, however, limited. Based on 
preliminary studies, enterolactone concentrations in breast tissue (~3 nmol/l, 
Hargreaves et al. 1999), nipple aspirate fluid (~3 nmol/l, Hargreaves et al. 1999) and 
amniotic fluid (~10 nmol/l, Adlercreutz et al. 1999) are comparable with those in 
serum but higher than those in prostate tissue (93 vs. 28 nmol/l, Hong et al. 2002), 
prostatic fluid (68-549 vs. 13-21 nmol/l, Morton et al. 1997a), and breast cyst fluid 
(63 vs. 17 nmol/l, Boccardo et al. 2003). 
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Sweden 492 F4 51.2-58.16 ENL 20.4-22.92,5 Hulten et al. 2002 
Sweden  342 M4 Middle-aged ENL 13.82 Stattin et al. 2002 
II. Urine     
Australia 144 F4 30-84 ENL 3.18, END 0.38 Ingram et al. 1997 
China 250 F4 25-64 ENL 6.3 ± 8.69, END 0.9 ± 1.79       Dai et al. 2002 
Finland 126 F 24-65 ENL 4.9 ± 3.110 Uehara et al. 2000 
Korea 75 F 52-65 ENL 1.5 ± 1.111, END 0.4 ± 0.511          Kim et al. 2002 
The Netherlands 268 F4 50-64 ENL 566 ± 35412 den Tonkelaar et al. 2001 
USA 49 F + 49 M 18-37 ENL 3.6 ± 4.68, END 1.3 ± 3.48  Lampe et al. 1999 
USA 199 F + M (61% F) 20-58 ENL 1.725,7, END 0.25,7 Valentin-Blasini et al. 2003 
M = male, F = female, ENL = enterolactone, END = enterodiol  
1Values are median or mean ± SD in nmol/l (plasma/serum) or µmol/24-h (urine) 
2Serum/plasma lignans analyzed by TR-FIA 
3Baseline value 
4Controls 
5Mean(s) 
6Serum/plasma lignans analyzed by ID-GC-MS/GC-MS 
7Serum/urinary lignans analyzed by HPLC, urinary lignans analyzed from spot sample and expressed in µmol enterolactone/l 
8Urinary lignans analyzed by ID-GC-MS from 72-h urine samples 
9Urinary lignans analyzed by LC-MS from overnight urine samples and results expressed in µmol enterolactone/g creatine 
10Urinary lignans analyzed by TR-FIA from 24-h urine samples 
11Urinary lignans analyzed by GC-MS from 24-h urine samples 
12Urinary lignans analyzed by TR-FIA from overnight urine samples and values are expressed in µmol enterolactone/mol creatine
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3.2.4 Reliability of lignan measurements 
Little work has been done to assess the reliability of serum and plasma or urinary 
lignan concentrations. The short-term reliability coefficient of serum enterolactone 
measurements has been reported to be 0.84 in samples collected on successive days 
(Horner et al. 2002), 0.79 in samples collected on five successive days within one 
week (Stumpf & Adlercreutz 2003), and 0.77 in samples collected on four Mondays 
within one month (Stumpf & Adlercreutz 2003). The long-term reliability of serum 
enterolactone measurements over a two-year period is somewhat lower, 0.55 
(Zeleniuch-Jacquotte et al. 1998). Reliability of 24-h urinary enterolactone 
concentration is comparable with that of serum measurements (Stumpf & 
Adlercreutz 2003), and as expected, reliability of the overnight urinary 
enterolactone-creatine ratio is poorer (den Tonkelaar et al. 2001, Stumpf & 
Adlercreutz 2003). 
3.2.5 Factors associated with serum and urinary lignans 
The content of plant lignans in the diet is often considered the most important 
determinant of serum and urinary lignan levels. Several small trials have shown that 
supplementation with flaxseed, the richest known source of mammalian lignans, 
causes a clear dose-dependent response in serum (Brzezinski et al. 1997, Morton et 
al. 1997b, Nesbitt et al. 1999, Tarpila et al. 2002) and urinary (Schultz et al. 1991, 
Lampe et al. 1994, Cunnane et al. 1995, Nesbitt et al. 1999, Hutchins et al. 2000) 
lignan concentrations. Depending on the level of intake and the compound sought, 
this increase has been up to 285-fold in urine (Nesbitt et al. 1999) and 6.6-fold in 
serum (Brzezinski et al. 1997). Moreover, not only flaxseed or other lignan-rich 
foods (Juntunen et al. 2000, Mazur et al. 2000, Pool-Zobel et al. 2000, Jacobs et al. 
2002, Vanharanta et al. 2002a) but also a change in dietary habits towards a diet 
high in vegetables and fruit has caused an increase in serum (Stumpf et al. 2000a) 
and urinary (Hutchins et al. 1995) lignan levels. However, high interindividual 
variation in the response exists. The results of supplementation studies involving a 
minimum of 15 subjects were collected and are displayed in Table 4. 
In larger studies, intake of fiber has been positively associated with serum and 
urinary level of lignans (Adlercreutz et al. 1982, 1987, Lampe et al. 1999, Rowland 
et al. 1999, Pietinen et al. 2001, Horner et al. 2002, Vanharanta et al. 2002b). Serum 
enterolactone concentration has also been positively associated with consumption of 
vegetables (Horner et al. 2002, Vanharanta et al. 2003) and negatively associated 
with intake of fat (Horner et al. 2002, Vanharanta et al. 2003). No consistent 
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association has been found for intake of alcohol (Horner et al. 2002, Vanharanta et 
al. 2003) or consumption of fruit (Lampe et al. 1999, Pietinen et al. 2001, Horner et 
al. 2002, Vanharanta et al. 2003). Lignan levels have tended to be higher in older 
persons (Rowland et al. 1999, Horner et al. 2002) and persons with a low-normal 
body mass index (BMI, Horner et al. 2002, Hulten et al. 2002, Vanharanta et al. 
2003). Demographic characteristics and intake of fiber, alcohol, and caffeine 
accounted for 22% of variation in plasma enterolactone among young American 
volunteers (Horner et al. 2002), whereas in middle-aged Finnish men only about 
10% of variation was explained by fiber, alcohol, saturated fatty acid, and vegetable 
consumption, BMI, constipation, and the number of bronchitis episodes diagnosed 
during the lifetime (Vanharanta et al. 2003).  
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Table 4. Results of selected supplementation studies (n 15).  
Population  Age (years) Supplementation  Duration Lignans at baseline1 Change (%)2  Reference 
I. Serum/plasma       
78 F 43-65 Flaxseed3 12 weeks  ENL 155.3 ± 43.34                           
END 35.7 ± 20.04 
 
ENL 97 (62%)              
END 55 (155%) 
Brzezinski et al. 1997 
18 M + 21 F M: 435                       
F: 435 
Whole meal rye bread6  
 
                                                            
White wheat bread6 
4 weeks 
                                      
4 weeks 
                                        
M: ENL 28.1 ± 3.84                                                                 
F: ENL 39.3 ± 4.44                                                   
 
M: ENL –3 (-9%)                       
F: ENL –0.4 (-1%) 
M: ENL –16 (-56%)               
F: ENL –25 (-62%)   
Juntunen et al. 2000 
85 M + F 35-49  Diet high in vegetables and fruit 12 weeks ENL 12.2 (10.4-19.3)7 
 
ENL 7 (60%) Stumpf et al. 2000a 
18 M + 62 F  
15 F + M 
M: 46 ± 108 
F: 43 ± 118    
Flaxseed food9 
Flaxseed food9 
4 weeks 
4 months 
ENL 26-305 
ENL 335     
 
ENL 19-26 (63-200%) 
ENL 37 (112%) 
 
Tarpila et al. 2002 
15 M 
29 M 
29 M 
30-69 
30-69 
30-69 
Rye bread high in phloem10 
Rye bread low in phloem10 
Placebo rye bread without phloem10 
4 weeks 
4 weeks 
4 weeks 
ENL ~425 
ENL ~215 
ENL ~385 
ENL 27 (64%) 
ENL 25 (219%) 
ENL 2 (5%) 
Vanharanta et al. 2002a 
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II. Urine 
      
18 F 20-34  Flaxseed powder 10 g/d 3 months ENL 3.2 ± 1.511             
END 1.1 ± 1.111 
ENL 25 (780%)               
END 18 (1689%) 
Lampe et al. 1994 
11 M + 9 F Young Soy diet  
                                                        
Carotenoid diet 
                                                      
Cruciferous diet 
9 days  
                            
9 days 
                                 
9 days 
                                  
ENL 3.2 ± 0.511                 
END 0.5 ± 0.111 
 
ENL –3 (-78%)     
END –0.4 (-80%)                  
ENL –1.7 (-113%)           
END 0 (0%) 
ENL –0.7 (-22%)     
END 0.9 (180%) 
Kirkman et al. 1995 
31 F 52-82  Flaxseed 5 g/d  
Flaxseed 10 g/d 
7 weeks 
7 weeks                                             
 
ENL 3.4 (2.9-4.1)12                                   
END 0.4 (0.3-0.5)12 
 
ENL 21 (626%)                  
END 1 (250%) 
ENL 53 (1553%)     
END 3 (700%) 
Hutchins et al. 2000 
M = male, F = female, ENL = enterolactone, END = enterodiol 
1Values are means ± SD in nmol/l (plasma/serum) or mol/24-h (urine) 
2Values are nmol/l (change in plasma/serum lignans) or mol/24-h (change in urinary lignans) 
3Diet included 2 teaspoons flaxseed/d (providing lignans ~4 mg/g) and soy products ~500 g/d 
4Mean ± SEM 
5Mean(s) without SD 
6Mean consumption of whole meal rye bread was 219 g/d in men (providing lignans ~0.54 mol/d) and 162 g/d in female (providing lignans ~0.40 mol/d). Mean consumption 
of white wheat bread was 200 g/d in men (providing lignans ~0.06 mol/d) and 153 g/d in female (providing lignans ~0.05 mol/d) 
7Median (95% CI) 
8Mean ± SD 
9Flaxseed foods provided lignans ~8 mg/d 
10Daily amount of study bread was 70 g, providing lignans 20 773 nmol/d in high-phloem group, 12 331 nmol/d in low-phloem group, and 758 nmol/d in placebo group 
11Least-squares mean ± SE 
12Geometric mean (95% CI)
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3.3 Biological effects of lignans 
Numerous biological effects for dietary lignans have been proposed during the past 
twenty years. Evidence is, however, sparse and inconsistent and mostly limited to in 
vitro experiments.  
Enterolactone has structural similarities to endogenous estrogens (Figure 3) 
suggesting possible estrogenic activity. Thus far, binding affinity of enterolactone to 
estrogen receptor (ER) has not been examined. In classical α- or β-type ER-
mediated pathways, enterolactone has shown neither estrogenic nor antiestrogenic 
activity (Saarinen et al. 2000). However, enterolactone has exerted both weak 
estrogenic and weak antiestrogenic effects in human cell lines (Welshons et al. 1987, 
Hirano et al. 1990, Mousavi & Adlercreutz 1992, Sathyamoorthy et al. 1994, Wang 
& Kurzer 1997, 1998, Schultze-Mosgau et al. 1998, Sung et al. 1998). The 
concentrations tested have been many-fold than those measured in humans  
(Table 3). Moreover, no estrogenic activity of enterolactone has been observed in 
vivo (Setchell et al. 1981a, Waters & Knowler 1982, Saarinen et al. 2000, 2001), but 
some antiestrogenic effects have been reported in one preliminary study (Waters & 
Knowler 1982). 
Figure 3. Chemical structure of enterolactone and estradiol. 
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stimulated the synthesis of sex hormone-binding globulin (SHBG) in the liver 
(Adlercreutz et al. 1992) and decreased the binding of steroid hormones to SHBG 
(Martin et al. 1996, Schottner et al. 1997, 1998). These effects, in theory, could 
induce lower lifetime exposure to sex hormones, which potentially could lower the 
risk of breast and prostate cancers. However, no aromatase inhibition was observed 
in vivo (Saarinen et al. 2002), and lignan supplementation has rather minor effects 
on serum sex hormones and SHBG in human clinical trials (Schultz et al. 1991, 
Phipps et al. 1993, Hutchins et al. 2001, Brooks et al. 2004).  
On the basis of in vitro studies, enterolactone has also been suggested to possess 
antioxidant activity (Kitts et al. 1999, Pool-Zobel et al. 2000, Prasad 2000, Saarinen 
et al. 2000) and the ability to inhibit the Na+K+ pump (Braquet et al. 1986). The 
relevance of these findings in the understanding of enterolactone action in vivo is, 
however, unclear. 
In animal models, some evidence of chemopreventive effects of lignans has 
emerged. A lignan-rich diet has retarded or reduced experimentally induced tumors 
in several tissues, including the mammary gland (Serraino & Thompson 1991, 
Thompson et al. 1996, Rickard et al. 1999, 2000, Tou & Thompson 1999, Saarinen 
et al. 2000, 2001, 2002, Ward et al. 2000, Dabrosin et al. 2002) and prostate (Zhang 
et al. 1997, Landstrom et al. 1998, Bylund et al. 2000). However, only a few studies 
(Thompson et al. 1996, Saarinen et al. 2000, 2002) used purified lignans, and thus, it 
is difficult to know whether the observed chemopreventive effects can be attributed 
directly to lignans rather than to other components of lignan-rich foods. Moreover, 
serum enterolactone concentrations measured in these experimental models have 
been very high compared with those measured in humans (Table 3). Therefore, in 
the absence of solid data from clinical and epidemiological studies, the question of 
whether lignans have chemopreventive effects in humans remains open. 
 
3.4 Health effects of lignans  
3.4.1 Breast cancer 
Breast cancer is the most common cancer in women worldwide (Parkin et al. 1999). 
Established risk factors for breast cancer are associated with hormonal and 
reproductive factors (Kelsey et al. 1993, Key et al. 2001, Bianchini et al. 2002). 
However, these factors, including age, early menarche, nulliparity, late age at first 
pregnancy, late menopause, family history, and obesity in postmenopausal women, 
are estimated to explain less than half of breast cancer cases (Hankin 1993). Thus, 
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large gaps remain in current knowledge of etiology of the disease. Moreover, many 
of the known risk factors are relatively unmodifiable in a practical sense, thus 
limiting the means for primary prevention. Identification of new modifiable risk 
factors, such as dietary factors, has therefore been an area of much interest. Thus far, 
research concerning the effects of diet on risk of cancer has uncovered few definite 
effects and left much uncertainty (Willett 2001, Key et al. 2002, 2004). 
In the past decade, lignans have received particular attention. The literature 
examining the association between lignan exposure and risk of breast cancer is, 
however, limited and inconclusive. A descriptive study with seven breast cancer 
cases and twenty controls was the first to detect lower urinary excretion of 
enterolactone in breast cancer patients than in controls (Adlercreutz et al. 1982). To 
date five epidemiological studies have assessed the association between blood or 
urinary enterolactone concentration and the risk of breast cancer (Table 5), and three 
of these studies have found an inverse association. In these case-control studies, risk 
reduction between high and low serum (Pietinen et al. 2001) or urinary (Ingram et 
al. 1997, Dai et al. 2002) enterolactone concentration has been approximately 60%. 
Findings from two prospective studies contradict those of the case-control studies, 
with no association being observed for urinary enterolactone excretion (den 
Tonkelaar et al. 2001) and only a marginal inverse association for serum 
enterolactone concentration (Hulten et al. 2002). Moreover, no associations have 
been found between dietary intake of plant or mammalian lignans and breast cancer 
risk in cohort studies (Horn-Ross et al. 2001, 2002b, Keinan-Boker et al. 2004). In 
case-control studies, a high intake of mammalian lignans was associated with a 
lower risk of premenopausal breast cancer (McCann et al. 2002, Linseisen et al. 
2004) but not with a lower risk of postmenopausal breast cancer (McCann et al. 
2002). All epidemiological studies in which the association between lignan or 
enterolactone exposure and risk of breast cancer has been examined have been 
collected in Figure 4. In addition to these studies, in a very small prospective study, 
breast cancer risk was inversely associated with serum enterolactone concentration 
(RR=0.36, 95% CI 0.14-0.93, Boccardo et al. 2004) but not with enterolactone 
concentration in cyst fluid (RR=0.70, 95% CI 0.22-2.27, Boccardo et al. 2003). 
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Figure 4. Association between lignan or enterolactone exposure and risk of  
breast cancer. OR/RR with 95% CI for the highest vs. lowest  
exposure groups is presented. 
 
 
 
 
 
 
 
 
 
 
 
References: 1Ingram et al. 1997, 2Pietinen et al. 2001, 3Dai et al. 2002,  
4McCann et al. 2002, 5Linseisen et al. 2004, 6den Tonkelaar et al. 2001,  
7Horn-Ross et al. 2001, 8Horn-Ross et al. 2002b, 9Hulten et al. 2002,  
10Keinan-Boker et al. 2004
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Table 5. Epidemiological studies on the relationship between lignans and cancer. 
Age (years) Medium  Study design Number of 
cases 
Number of 
controls/ 
cohort 
Adjusted OR/RR1 (95% CI)  Reference  
I. Breast cancer      
25-75 Serum Case-control  194 208 ENL 0.38 (0.18-0.77) Pietinen et al. 2001 
51.2-58.12 Plasma Cohort 248 492 ENL 1.1 (0.7-1.7) Hulten et al. 2002 
543 Urine4 Case-control  144 144 ENL 0.36 (0.15-0.86) Ingram et al. 1997 
50-64 Urine5 Cohort 88 268 ENL 1.43 (0.79-2.59)6  den Tonkelaar et al. 2001 
25-64 Urine5 Case-control  250 250 ENL 0.42 (0.25-0.39) Dai et al. 2002 
35-79 Diet7 Cohort 1 272 1610 SECO 1.3 (1.0-1.6)               
MAT 1.1 (0.89-1.5) 
Horn-Ross et al. 2001 
21-103 Diet7 Cohort 711 111 526 SECO 1.4 (1.0-1.8)            
MAT 1.1 (0.8-1.4) 
Horn-Ross et al. 2002b 
Premenopausal 
Postmenopausal 
Diet7 Case-control  301 
493 
316 
494 
ENL + END 0.49 (0.32-0.75) 
ENL + END 0.72 (0.51-1.02) 
McCann et al. 2002 
49-70 Diet7 Cohort 280 15 555 ENL + END 0.70 (0.46-1.09) Keinan-Boker et al. 2004 
< 50  Diet7 Case-control 278 666 SECO 1.1 (0.73-1.7)            
MAT 0.58 (0.37-0.94)                       
SECO + MAT 1.1 (0.72-1.7) 
ENL + END 0.61 (0.39-0.98) 
Linseisen et al. 2004 
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II. Prostate cancer      
Middle-aged and old Serum Cohort 794 2550 ENL 1.08 (0.83-1.39)8 Stattin et al. 2002 
60.6 ± 6.99 Diet7 Case-control  83 107 SECO 1.20 (0.65-2.21)             
MAT 0.89 (0.47-1.66) 
Strom et al. 1999 
III. Other cancers      
Colorectal cancer      
M + F (age not reported) Plasma Cohort 117 232 ENL 0.99 (0.52-1.88) Lundin 2001 
Endometrial cancer       
35-79 F Diet7 Case-control 500 470 SECO 0.68 (0.21-0.85)             
MAT 1.6 (0.99-2.4) 
Horn-Ross et al. 2003 
Ovarian cancer       
40-85 F Diet7 Case-control 124 696 SECO + MAT 0.43 (0.21-0.85) McCann et al. 2003 
Testicular cancer       
18-55 M Diet7 Case-control  159 136 SECO + MAT 0.96 (0.11-8.09) 
ENL + END 0.73 (0.21-2.56) 
Walcott et al. 2002 
Thyroid cancer      
20-74 F Diet7 Cohort 608 558 SECO 0.56 (0.35-0.89)                
MAT 0.72 (0.46-1.10) 
Horn-Ross et al. 2002a 
M = male, F = female, ENL = enterolactone, END = enterodiol, MAT = matairesinol, SECO = secoisolariciresinol 
1Highest vs. lowest group 
2Mean(s) 
3Median  
472-h urine samples 
5Overnight urine samples 
6Crude OR, after adjustment <10% change in crude OR 
7Diet was assessed via a food frequency questionnaire 
8Crude RR 
9Mean ± SD
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3.4.2 Prostate cancer 
Prostate cancer is the leading cancer in males in most Western populations (Hsing et 
al. 2000). Despite this, its etiology remains largely unknown, with age, race, and 
family history of disease being the only established risk factors (Nomura & Kolonel 
1991). The observations that the incidence of latent prostate cancer is similar 
worldwide but the rate of invasive disease varies markedly (Hsing et al. 2000) 
support an important role for environmental factors, including diet, in the 
progression and clinical manifestation of this malignancy.  
Several dietary components have been studied with inconsistent findings (Giles & 
Ireland 1997, Schmitz-Drager et al. 2001, Key et al. 2004), emphasizing some of the 
current challenges in the epidemiology of prostate cancer. Due to their many 
biological actions, lignans have also been suggested to play a role in the prevention 
of prostate cancer. However, only a few epidemiological studies have been carried 
out (Table 5). High circulating enterolactone has not been associated with reduced 
risk of prostate cancer in a large prospective study based on population cohorts from 
Finland, Sweden, and Norway (Stattin et al. 2002), and no relationship between 
dietary intake of lignans and prostate cancer was observed in a case-control study 
conducted in the United States (Strom et al. 1999). 
3.4.3 Other types of cancer 
Some research has investigated the role of lignans in other cancers (Table 5). A high 
intake of lignans was associated with a reduced risk of endometrial (Horn-Ross et al. 
2003), ovarian (McCann et al. 2003) and thyroid (Horn-Ross et al. 2002a) cancers 
but no relationship was observer with testicular cancer (Walcott et al. 2002). Neither 
was as association observed between serum enterolactone and risk of colorectal 
cancer in a prospective study in Sweden (Lundin 2001). In addition, in a recent 
study of patients with hepatocellular carcinoma and cirrhosis in Italy, no differences 
in lignan intake between these two groups were found (Lei et al. 2002). 
3.4.4 Other diseases 
Due to several biological activities, lignans are hypothesized to also protect against 
other chronic diseases. Intervention studies assessing the effects of a lignan-rich diet 
on risk factors of cardiovascular disease (CVD) have been few, but they have 
consistently reported a reduction in serum lipids (Jenkins et al. 1999, Lucas et al. 
2002). Consumption of lignans has also been inversely associated with both plasma 
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triglycerides and CVD risk metabolic score in middle-aged women in the United 
States (de Kleijn et al. 2002). In a prospective study of 167 middle-aged Finnish 
men with acute coronary event and their matched controls, men in the highest 
quartile of serum enterolactone concentration had a 59% (95% CI 24%-78%) lower 
risk of acute coronary event than men in the lowest quartile (Vanharanta et al. 1999). 
High serum enterolactone was also associated with reduced risk of coronary heart 
disease mortality (RR=0.44, 95% CI 0.20-0.96) and CVD-related mortality 
(RR=0.55, 95% CI 0.29-1.01) but had a weaker association with all-cause mortality 
(RR=0.76, 95% CI 0.52-1.12) (Vanharanta et al. 2003). 
Lignans have been hypothesized to exert hormonal effects, thereby playing a role in 
bone metabolism. However, results of two human studies are inconclusive; high 
urinary enterolactone excretion had a positive association with bone mineral density 
in Korean postmenopausal women (Kim et al. 2002), but it was associated with a 
higher rate of bone loss in postmenopausal women in the Netherlands (Kardinaal et 
al. 1998). Moreover, flaxseed supplementation has not had a beneficial effect on 
biomarkers of bone metabolism in animals (Ward et al. 2001a, 2001b) or humans 
(Lucas et al. 2002).  
The potential for phytoestrogens to alleviate symptoms associated with menopause, 
particularly hot flashes, is an area of active research. However, most of the attention 
has focused specifically on isoflavonoids (Albertazzi & Purdie 2002). In two studies 
in which supplementation included a combination of flaxseed and soy, no consistent 
alleviation of menopause symptoms was observed (Brzezinski et al. 1997, Dalais et 
al. 1998). 
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4 AIMS OF THE STUDY 
The general aim of this study was to examine the determinants of serum 
enterolactone concentration and to assess the association between serum 
enterolactone concentration and the risk of breast and prostate cancers.  
 
Specific aims were as follows: 
 
1. To define the distribution of serum enterolactone concentration among 
Finnish adults.  
2. To examine the cross-sectional association between serum enterolactone 
concentration and dietary factors, including consumption of lignan-containing 
foods and intake of lignans.  
3. To examine the cross-sectional association between serum enterolactone 
concentration and selected background characteristics.   
4. To investigate the cross-sectional association between serum enterolactone 
concentration and recent use of antimicrobials.  
5. To assess the relationship between serum enterolactone concentration and the 
risk of breast and prostate cancers. 
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5 MATERIALS AND METHODS 
The material of this work came from two large studies. The cross-sectional 
FINRISK surveys were used to define the distribution of serum enterolactone 
concentration and to examine its determinants (Studies I-III) as well as to assess the 
association between serum enterolactone concentration and risk of breast cancer 
(Study IV). The Alpha-Tocopherol Beta-Carotene Cancer Prevention (ATBC) study 
was used to assess the association between serum enterolactone concentration and 
risk of prostate cancer (Study V).  
 
5.1 The FINRISK and FINDIET surveys 
The comparable cross-sectional FINRISK surveys have been carried out every fifth 
year since 1972 to assess the levels and trends of CVD risk factors in Finland 
(Vartiainen et al. 2000). The first two surveys were conducted in two eastern Finnish 
provinces, North Karelia and Kuopio. The surveys were expanded to southwestern 
parts of Finland in 1982, to the Helsinki metropolitan area in 1992, and to the 
northern province of Oulu in 1997. The target population consisted of men and 
women aged 25-64 years living in the survey areas. In 1997, the sample also 
included people aged 65-74 years. For each survey, an independent random sample 
stratified by 10-year age group, area, and sex (at least 250 subjects per cell) was 
drawn from the population register. As part of the FINRISK survey, the FINDIET 
dietary survey has been conducted since 1982. 
5.1.1 Study population 
S t u d i e s  I - I I I  
Studies I-III comprised data collected in the FINDIET survey in 1997 (Figure 5), the 
protocol of which was approved by the Ethics Committee of the National Public 
Health Institute. For this dietary survey, a subsample of 4000 subjects (40%) was 
randomly selected from the FINRISK participants, with 2862 (72%) subsequently 
participating in the survey (FINDIET 1997 Study Group 1998). A serum sample for 
enterolactone analysis was available for 2753 subjects, and of these, subjects who 
had used antimicrobials within the past three months (n=373) were excluded from 
Study I (n=2380). Intake of lignans was assessed among all FINDIET participants; 
ten subjects with extremely high intake (>17 mg/day) were subsequently excluded 
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from Study II (n=2852). All subjects for whom serum enterolactone concentration 
was available were included in the analysis of the association between intake of 
lignans and serum enterolactone concentration (n=2744). These analyses were done 
separately for those who had not used antimicrobials for one year prior to the 
examination (n=1784) and those who had (n=960). All FINDIET participants for 
whom information on serum enterolactone concentration and use of antimicrobials 
was available were included in Study III (n=2753). Some new analyses summarizing 
data from Studies I-III were performed. These analyses included subjects for whom 
information on serum enterolactone concentration, selected background variables, 
dietary factors, and use of antimicrobials was available (n=2539; n=1202 for men 
and n=1337 for women). 
S t u d y  I V  
Subjects of Study IV were participants of FINRISK surveys carried out between 
1982 and 1997. A total of 19 000 women aged 25-74 years were included. The 
participation rate across cohorts varied from 76.2% to 85.0%, with the final sample 
comprising 15 497 women. 
Incident cases of breast cancer (ICD-10 code C50) were identified through Finnish 
Cancer Registry. By the end of January 2002, 465 breast cancers had been identified 
among survey participants. For 16 subjects who had been diagnosed with breast 
cancer twice, only the first case was included, and the 13 cases who had participated 
in several surveys were included in only their first survey cohort. Those who had 
breast cancer diagnosed prior to participation in the survey (n=127) were excluded; 
thus, 322 breast cancer cases were eligible for our study.  
For each case, a control frequency-matched to case by study cohort, age group (the 
same 5-year age group, i.e. from 25-29 years up to 70-74 years), and study area was 
selected. A serum sample for enterolactone analysis was available for 206 cases and 
215 controls; the proportions of subjects providing a blood sample in the 1982, 
1987, 1992, and 1997 cohorts were 58%, 61%, 92%, and 66%, respectively. The 
corresponding numbers of cases and controls from these cohorts were 88 and 95, 47 
and 52, 49 and 49, and 22 and 19. Breast cancer subjects aged 51 years or less at the 
time of diagnosis were classified as premenopausal (n=69) and those over 51 years 
as postmenopausal (n=137, Luoto et al. 1994). 
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Figure 5. Flow chart of study participants (Studies I-III and summary analyses). 
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5.1.2 Data collection 
H e a l t h  e x a m i n a t i o n   
Subjects were invited to a health examination at a local health care center, where a 
fasting (minumum 4 h) venous blood sample was drawn. In addition, weight and 
height were measured, and BMI was computed as weight (kg) divided by height 
squared (m2). The following cut-off points for BMI were used in Studies I-II: under 
20.1 kg/m2 underweight, 20.1-25.0 kg/m2 normal weight, 25.1-30.0 kg/m2 
overweight, 30.1-35.0 kg/m2 obese, and over 35.0 kg/m2 severely obese. In Studies 
III-IV, BMI was used as a continuous variable. 
H e a l t h  a n d  l i f e s t y l e  q u e s t i o n n a i r e  
In each survey, information on health, lifestyle, and socioeconomic factors was 
collected by a self-administered questionnaire completed at the examination. 
Educational levels were formed by dividing subjects born in the same year into 
tertiles based on their total years of education. Smoking history was assessed using a 
standard set of questions, and according to responses, participants were classified 
into three groups: those who had never smoked (nonsmokers), those who had quit 
smoking (ex-smokers), and those currently smoking (current smokers).  
In Study I, alcohol consumption was calculated from the questionnaire, covering the 
frequency of use and the average portion of beer, wine, and spirits consumed during 
the previous 12 months. The following cut-off points for weekly ethanol intake were 
used for men: 0 g none, 1-139 g low, 140-280 g moderate, and over 280 g heavy. 
The corresponding values for women were 0 g, 1-104 g, 105-190 g, and over 190 g. 
Subjects were also divided into three categories (poor, satisfactory, good) by self-
reported physical status. Furthermore, participants were asked whether they had 
suffered from constipation during the preceding month (30 days); the response 
alternatives were “yes” and “no”.  
D i e t a r y  a s s e s s m e n t  
A food frequency questionnaire (FFQ) including 38 food items was used in the 1997 
survey as part of the self-administered questionnaire. The consumption of whole-
grain products was quantified from the FFQ by summing up the frequency of 
consumption as servings per month of rye bread, crisp bread, porridge, and cereals. 
Consumption of vegetables was calculated by summing up of the frequency of 
consumption of salad vegetables, roots, legumes, and vegetable dishes, and 
consumption of fruit and berries by summing up the frequency of consumption of 
fruit, berries, and fruit and berry juices. For the analyses of Study I, subjects were 
divided into tertiles by frequency of consumption of whole-grain products, 
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vegetables, and fruit and berries. In Study III, the frequencies of consumption of all 
lignan-containing foods, i.e. whole-grain products, vegetables, and fruit and berries, 
were summed.  
In Study II, dietary intake was assessed using a 24-h recall. To estimate validity and 
repeatability of this 24-h recall, a 48-h dietary recall and a 3-day food record were 
collected from a randomly chosen subpopulation of the same study (n=223 and 
n=334, respectively). Intake of lignans, matairesinol, secoisolariciresinol, and their 
sum was quantified by a recently developed phytoestrogen database (Valsta et al. 
2003). 
D a t a  o n  u s e  o f  a n t i m i c r o b i a l s  
Data on the use of antimicrobials (Study III) were based on the nationwide 
prescription register of the Social Insurance Institution. Since 1995, all prescriptions 
reimbursed by the National Sickness Insurance Scheme have been registered and 
classified according to the Anatomical Therapeutic Chemical (ATC) system. Oral 
antibacterials included tetracyclines, amoxicillin and other penicillins with an 
extended spectrum, phenoxymethylpenicillin and other beta-lactamase-sensitive 
penicillins, cloxacillin and other beta-lactamase-resistant penicillins, combined 
penicillins, cephalosporins, sulfonamides and trimethoprims, macrolides and 
lincosamides, fluoroquinolone antibacterials, and steroid antibacterials. Based on the 
total number of antimicrobial purchases, subjects were divided into five groups 
(none, 1, 2, 3, and at least 4), and based on time from last purchase into seven 
groups (under 2 months, 2-4 months, etc., to over 12 months). 
 
5.2 The Alpha-Tocopherol Beta-Carotene  
Cancer Prevention study 
The ATBC study was a randomized, double-blind, placebo-controlled trial aimed at 
determining whether daily supplementation with -tocopherol, -carotene, or both, 
would reduce the incidence of lung cancer and other cancers (The Alpha-Tocopherol 
Beta Carotene Cancer Prevention Study Group 1994). The ATBC study was a joint 
project between the National Public Health Institute of Finland and the National 
Cancer Institute of the United States. The institutional review boards of these two 
institutions approved the study protocal. Written informed consent was obtained 
from all study participants at baseline. 
Participants were screened by a postal questionnaire from amongst all men aged 50-
69 years and living in the southwestern part of Finland (n=209 406). Men who were 
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current smokers (smoked at least five cigarettes per day) and willing to participate 
were invited to undergo baseline examinations (n=42 957). Exclusion criteria were 
previous malignancy other than nonmelanoma skin cancer, severe angina, chronic 
renal insufficiency, cirrhosis of the liver, chronic alcoholism, anticoagulant therapy, 
use of supplements containing vitamin E (>20 mg/d), vitamin A (>20 000 IU/d), or 
-carotene (>6 mg/d), and other medical problems, such as psychiatric disorders or 
physical disability, that might limit long-term participation. A total of 29 133 men 
eligible for the trial were randomized into one of four intervention regimens:  
-tocopherol (50 mg/d), -carotene (20 mg/d), both, or neither (placebo). 
Recruitment began in April 1985 and continued until June 1988. Participants were 
followed until death or the end of the trial (April 30, 1993, median follow-up 6.1 
years). 
5.2.1 Study population 
A total of 246 prostate cancers were identified among ATBC study participants 
between May 1985 and April 1993, primarily through the Finnish Cancer Registry 
and the Register of Causes of Death. Medical records were reviewed centrally by 
two study oncologists to confirm diagnoses. Prostate cancers with available 
histology or cytology (98%) were also reviewed by pathologists. For each case, a 
control matched by age (±1 year), date (± 28 days) of baseline blood collection, 
intervention group, and local study area was selected. A blood sample for serum 
enterolactone analysis was available for 233 cases and 222 controls, leaving 214 
case-control pairs for analysis. 
5.2.2 Data collection 
Before randomization, each participant attended baseline examinations where fasting 
venous samples were taken and height and weight were measured. Information on 
medical history, smoking habits, education, physical activity, and dietary history 
was collected by questionnaires completed at the examinations. 
 
5.3 Assay of serum samples 
Fasting venous samples were drawn from the subjects at the examinations. Serum 
was separated, divided into 1-ml aliquots, and stored in glass vials either at –20ºC 
(Studies I-IV) or at –70ºC (Study V) until analysis of enterolactone. 
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Enterolactone analysis was performed by time-resolved fluoroimmunoassay (TR-
FIA, Adlercreutz et al. 1998) with slight modifications (Stumpf et al. 2000b). A 
more rapid modification was used in Studies I-III because of the high number of 
serum samples. 
The TR-FIA method used in Studies IV-V was briefly as follows: 250 µl (Study IV) 
or 150 µl (Study V) of serum was incubated with 250 µl (Study IV) or 150 µl  
(Study V) of hydrolysis reagent containing 2 U/ml sulfatase and 0.2 U/ml β-
glucuronidase overnight at 37°C. After hydrolysis, the free enterolactone and 
hydrolyzed conjugates were extracted twice with 1.5 ml of diethyl ether. Diethyl 
ether was evaporated to dryness in a water bath, after which the dry residue was 
dissolved in 250 µl (Study IV) or 150 µl (Study V) of assay buffer. A sample was 
divided into two subsamples, and enterolactone of both subsamples was analyzed by 
TR-FIA using the VICTOR 1420 multilabel counter (Wallac Oy, Turku, Finland). 
Subsamples were analyzed in the same laboratory batch, and the mean value of these 
two measurements was used. Matched case-control sets of Study V were also 
analyzed in the same laboratory batch, and laboratory personnel were blinded to the 
case-control status of samples. All of the batches were analyzed with two quality 
control samples going through the whole method. The concentrations of quality 
control samples and their respective interassay coefficients of variation (CV) in 
Study IV were 8.9 nmol/l and 11.5%, and 20.2 nmol/l and 7.0%, and in Study V  
3.2 nmol/l and 16.9%, and 12.4 nmol/l and 12.5%. One additional quality control 
sample with a concentration of 48.2 nmol/l and a CV of 9.3% in Study IV, and  
110 nmol/l and 8.2% in Study V controlled for TR-FIA. 
The more rapid modification of TR-FIA used in Studies I-III is briefly as follows:  
50 µl of serum was incubated with 50 µl of hydrolysis reagent containing 2 U/ml 
sulfatase and 0.2 U/ml β-glucuronidase overnight at 37°C. Unlike standard TR-FIA, 
no extraction was performed, instead enterolactone was directly measured. The 
concentrations of quality control samples and their respective CVs were 4 nmol/l 
and 16.8%, 14 nmol/l and 10.1%, and 59 nmol/l and 13.1%. 
The more rapid modification of TR-FIA tends to yield 15-30% higher results 
than the TR-FIA method with extraction. To enable comparison of results with 
previous studies, an equation between the modified TR-FIA and the standard 
TR-FIA with extraction was formed by analyzing 92 with both methods. The 
final results were calculated accordingly as follows: Final concentration = 
measured concentration × 0.934 - 11.03. 
 
In Study V, prostate-specific antigen (PSA) was determined by an immunometric 
method (Pettersson et al. 1995). 
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5.4 Statistical methods 
5.4.1 Studies I-III and summary analyses 
Dependence of serum enterolactone concentration on dietary factors, selected 
background variables, and use of antimicrobials was assessed by analysis of 
variance (Studies I-III). A mixed model for measurement error was used to test 
differences in intake of lignans between genders and in other background categories 
(Study II). In addition to 24-h dietary data, the model used a 48-h dietary recall and 
a 3-day food record; the attenuated regression coefficient (variance of 24-h recall 
data divided by variance of 3-day record data) was 1.18. T-test was used to analyze 
differences in means of log-transformed serum enterolactone concentrations 
between those who had not used antimicrobials and those who had (Study III). 
To summarize the determinants of serum enterolactone concentration, some new 
analyses combining data from Studies I-III were performed. In these analyses, 
similar categories of age, BMI, constipation, consumption of alcohol, education, 
physical status, smoking, and use of antimicrobials were used as in the original 
studies (see above). However, FFQ-based consumption of lignan-containing foods 
(i.e. whole-grain products, vegetables, and fruit and berries) and 24-h recall-based 
intake of lignans were used as continuous rather than categorical variables because 
of their linear associations with serum enterolactone concentration. To identify the 
most important determinants of serum enterolactone concentration, analysis of 
variance was used. All variables were initially included in the model, and 
nonsignificant variables were then one by one eliminated. In the final model, only 
the significant (p<0.05) variables were included. Because the distribution of serum 
enterolactone was skewed towards higher values, log-transformed enterolactone 
values were used, and all analyses were done separately for men and women.  
5.4.2 Studies IV-V 
The association between serum enterolactone concentration and risk of breast and 
prostate cancers was analyzed by conditional logistic regression using odds ratios 
(OR) with 95% confidence intervals (95% CI). Subjects were stratified into quartiles 
based on their serum enterolactone concentrations relative to the distribution in 
controls, and ORs were tested for linear trends across the quartiles using the Wald 
test with linear contrasts. Some subgroup analyses were conducted using serum 
enterolactone tertiles because of the smaller number of subjects in these subgroups. 
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6 RESULTS 
6.1 Serum enterolactone concentration and determinants 
6.1.1 Lifestyle factors (I) 
The distributions of serum enterolactone concentrations among study participants 
who had not used antimicrobials within the past three months are presented in 
Figure 6. The mean enterolactone concentrations (nmol/l) of men and women were 
17.3 (median 13.8) and 20.5 (median 16.6), respectively. 
Figure 6. Distribution of serum enterolactone concentrations (nmol/l)  
in men and women. 
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In men, serum enterolactone concentration was positively associated with self-
reported constipation and consumption of whole-grain products and fruit and 
berries. In women, serum enterolactone concentration was positively associated with 
consumption of vegetables, age, and self-reported constipation and negatively 
associated with smoking. Moreover, female participants of normal weight had 
significantly higher serum enterolactone concentrations than their underweight or 
obese peers. 
6.1.2 Intake of lignans (II) 
The distribution of lignan intake was very skewed to the right; 34% of subjects had 
intakes less than 100 g/d, and intake exceeded 0.5 mg/d in only 1.8%. The mean 
daily intake of lignans among men was 173 g (19 g/MJ), with a range of  
0-1044 g. The corresponding values for women were 151 g (23 g/MJ) and  
0-874 g. Thus, total lignan intake was higher in men than in women (p<0.0001), 
but women had a higher lignan density in their diet than men (p<0.0001). 
Secoisolariciresinol made up most of the lignan intake, over 70% in men and about 
80% in women. The main sources of secoisolariciresinol were fruit and berries (34% 
in men and 47% in women), followed by cereals (34% in men and 24% in women). 
Intake of matairesinol was derived mainly from cereals (90% in men and 85% in 
women), with rye intake accounting for over 80% of the total in both genders. 
Among those who had not used antimicrobials during the preceding year, serum 
enterolactone concentration was positively associated with intake of lignans; 
enterolactone concentration was 50% higher in the highest quintile of lignan intake 
than in the lowest. 
6.1.3 Use of antimicrobials (III) 
The mean serum enterolactone concentration (nmol/l) was significantly lower 
among those who had used oral antimicrobials up to 12-16 months before serum 
sampling than among nonusers, 16.4 (SD 14.3) vs. 19.3 (SD 16.1). Serum 
enterolactone concentration was negatively associated with the number of purchases 
and positively associated with the length of time from last purchase. Modest 
differences were also present between various antimicrobials, with macrolides 
tending to cause the strongest suppression in serum enterolactone concentration. 
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6.1.4 Summary analyses 
The range in serum enterolactone concentration among subjects included in the 
summary analyses was 0-183 nmol/l. Distributions of the concentrations were very 
skewed to the right in both genders, and 90% of subjects had a concentration under 
38 nmol/l. The mean serum enterolactone concentration (nmol/l) of men and women 
was 16.9 (SD 13.8, median 13.4) and 19.6 (SD 16.8, median 15.6), respectively. 
The results of summary analyses are presented in Figures 7 and 8. In men, log-
transformed serum enterolactone concentrations were 32% higher among subjects 
who had reported suffering from constipation, and increasing 11% when daily 
consumption of fruit and berries was increased by one serving. Concentrations also 
increased by 4% for each two-month period since the last antimicrobial purchase 
and decreased by 11% for each antimicrobial treatment. However, only 5% of the 
variation in concentration could be accounted for by including these four variables 
in the final model.  
Figure 7. Mean percentage change with 95% CI in log-transformed serum  
enterolactone concentrations in men. The model includes only  
significant determinants. 
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In women, log-transformed serum enterolactone concentrations were 18% higher 
among subjects who had reported suffering from constipation. Concentrations also 
increased 9% for each decade of age and 11% for daily consumption of vegetables 
being increased by one serving. Among smokers, log-transformed serum 
enterolactone concentrations were 29% lower than among nonsmokers. Each 
antimicrobial treatment also lowered serum enterolactone concentration by 11%. As 
BMI reached 30 kg/m2 or 35 kg/m2, log-transformed serum enterolactone 
concentrations were below those of normal BMI (BMI 20-25 kg/m2) by 33% and 
54%, respectively. Together these six variables in the final model explained 13% of 
the variation in serum enterolactone concentrations in women. 
Figure 8. Mean percentage change with 95% CI in log-transformed serum  
enterolactone concentrations in women. The model includes only  
significant determinants. 
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6.2 Serum enterolactone concentration and risk of cancer 
6.2.1 Breast cancer (IV) 
The mean serum enterolactone concentration (nmol/l) did not differ between breast 
cancer cases and controls, 25.2 (SD 22.2) vs. 24.0 (SD 21.3) (p=0.52). No 
significant association between serum enterolactone concentration and risk of breast 
cancer was found (Figure 9); the OR for the highest quartile was 1.30 (95% CI  
0.73-2.31) and p for trend was 0.48. Adjustment for alcohol consumption, BMI, 
physical activity, smoking, and years of education did not substantially affect the 
results (<7% change in ORs). Nor were any consistent associations observed when 
the analysis was restricted to subjects diagnosed at least 2 years after blood 
collection or when data were analyzed according to years of follow-up. 
Figure 9. Risk of breast cancer in serum enterolactone quartiles.  
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Two-thirds of cases had postmenopausal breast cancer. No consistent association 
was present between serum enterolactone concentration and risk of breast cancer 
when data were analyzed according to menopausal status (Figure 10). 
Figure 10. Risk of premenopausal and postmenopausal breast cancer in  
serum enterolactone tertiles.  
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Figure 11. Risk of prostate cancer in serum enterolactone quartiles. 
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Half of the cases had localized (stage 1 or 2) disease confined to the prostate. No 
consistent association was present between serum enterolactone concentration and 
risk of prostate cancer when data were analyzed according to extension of cancer  
(Figure 12).  
Figure 12. Risk of prostate cancer according to extension in serum  
enterolactone tertiles. 
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7 DISCUSSION 
7.1 Methodological considerations 
7.1.1 Serum enterolactone concentration  
Serum enterolactone concentrations were analyzed by TR-FIA in all studies. HPLC 
or GC combined with MS has typically been used for measuring lignans in body 
fluids, but these methods are expensive and time-consuming and are therefore not 
suitable for epidemiological studies involving a large number of samples. The 
immunoassay method has a relatively good reliability (CV% 7.0-16.9), and the 
correlations between the results obtained by TR-FIA and ID-GC-MS (a reference 
method) have been confirmed to be high (Adlercreutz et al. 1998, Stumpf et al. 
2000b, Uehara et al. 2000). However, some crossreactivities may occur with  
TR-FIA, i.e. other metabolites in addition to the target compound might be 
measured.  
Serum samples collected at baseline were stored at –20°C (Studies I-IV) or –70°C 
(Study V), and the time period from blood collection to enterolactone analysis 
varied from one to 20 years. It could be argued that the different storage 
temperatures and long storage time might affect the results, thus presenting a source 
of bias. Interestingly though, comparing the mean serum enterolactone 
concentrations between male participants of the cross-sectional survey (Studies I-III) 
and controls of the prostate cancer study (Study V), revealed no difference. Neither 
were significant differences in concentrations found between the four different study 
cohorts in the breast cancer study (Study IV). 
The possibility of measuring the exposure variable in serum involves some benefits 
in comparison with dietary assessment. Biomarkers, such as enterolactone, provide 
objective measures that are independent of reporting bias and provide an index of 
intake and subsequent metabolism. They therefore serve as a measure of 
bioavailability, which is relevant when nutritional significance and potential 
systemic effects of a compound are being considered. On the other hand, when only 
a single blood sample per subject is available, as in all of the present studies, it can 
be questioned whether blood enterolactone concentration at a single time-point 
reflects recent exposure rather than long-term exposure. The reliability coefficient of 
a single measurement of enterolactone appears, however, to be moderately high, 
from 0.84 for two days (Horner et al. 2002) to 0.55 for two years (Zeleniuch-
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Jacquotte et al. 1998), suggesting that a single serum enterolactone measurement is 
sufficient in epidemiological studies. 
7.1.2 Study populations and designs 
Studies I-IV were based on the cross-sectional FINRISK surveys. In each survey, a 
large, representative, population-based random sample was drawn. Despite a decline 
in the response rate over time, the participation rate remained relatively high 
(Vartiainen et al. 2000), supporting the generalizability of the results. However, 
more well-to-do population groups may be more likely to participate in these kinds 
of surveys, leading to some bias in results. The prostate cancer study was based on 
the ATBC trial, which was aimed at evaluating the effects of supplementation on the 
incidence of lung cancer. All participants were, therefore, current male smokers, 
restricting the generalizability of these results. Moreover, the in breast cancer study, 
the proportions of women with a blood sample available for enterolactone analysis 
varied between 58% and 92% in study cohorts; however, women who did not 
provide a blood sample were similar to those who did for all background variables 
studied. 
The cross-sectional design of the FINRISK surveys does not allow the temporality 
of associations to be considered in Studies I-III and also limits determination of how 
changes in variables actually affect serum enterolactone concentration. The 
prospective study design in the breast and prostate cancer studies ensured identical 
collection and handling of blood samples from case and control subjects, and 
matching for date of blood collection to eliminate possible bias due to degradation 
of enterolactone during storage. Moreover, the blood samples used were obtained 
years prior to the diagnoses of cancer, making the presence of clinical cancer at the 
time of blood donation unlikely. 
7.1.3 Dietary assessments and the phytoestrogen database 
Both FFQ and 24-h recall were used to assess diet. The FFQ used in Studies I and III 
had not been designed to assess the consumption of lignan-containing foods, and 
therefore, some foods with a high content of lignans, like seeds and nuts, were not 
included in the questionnaire. Moreover, the questionnaire assessed the diet during 
the previous 12 months, whereas enterolactone probably has a relatively short half-
life in the body (Morton et al. 1997b, Nesbitt et al. 1999, Mazur et al. 2000). This is, 
of course, only a problem in situations where dietary habits vary widely. 
The dietary data in Study II were collected by a 24-h dietary recall. The main 
concern with this method is whether diet in one day represents the usual diet. In the 
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case of lignan intake, the 24-h recall method could be deemed suitable because 
lignans are widely distributed in plant foods (Mazur 1998, Mazur & Adlercreutz 
1998, Liggins et al. 2000), and these foods are most likely consumed daily. 
However, some foods with very high amounts of lignans, such as flaxseed, are 
probably consumed not on a daily but on a weekly or a monthly basis, and this may 
lead to some misclassification. Naturally, a more representative dietary data by, for 
example, collecting a 24-h recall during all four seasons would have been 
advantageous. 
The dietary questionnaire used in the ATBC study has been validated, and its 
reproducibility and validity were found to be satisfactory (Pietinen et al. 1988). 
The recently developed phytoestrogen database (Valsta et al. 2003) was used to 
estimate intake of lignans (Study II). A strength of the database is that most of the 
food analyses have been performed in Finland using typical Finnish foods. 
However, in most cases, only a small number of samples were available, which is a 
cause for concern because lignan content of a food can vary substantially according 
to breed, crop season and location, processing method, and other variables. 
Moreover, several new and abundant enterolactone precursors, not included in our 
database, have recently been found (Saarinen et al. 2000, Wang et al. 2000, 
Heinonen et al. 2001). 
7.1.4 Register-based study variables 
Data on antimicrobial purchases (Studies I-III) were based on a nationwide drug 
register. At the time of the study, the register included over 95% of Finnish 
pharmacies with the only pharmacies excluded being those without a computer 
system for handling prescriptions. Moreover, we had no data on antimicrobials 
received in hospitals or antimicrobials that were not included in the reimbursement 
system due to low price (under 50 FIM, ~8.5∈). However, only 13% of all 
antimicrobials were used in hospitals, and most of the inexpensive drugs are 
phenoxymethylpenicillin, sulpha-trimethoprim, and nalidixic acid, which all have 
been suggested to have a minor impact on microflora (Nord et al. 1986, Hooker & 
DiPiro 1988). 
Incident cases of breast and prostate cancers were identified primarily through the 
Finnish Cancer Registry. The register covers over 99% of cancers identified in 
Finland, and its accuracy is high (Teppo et al. 1994, Korhonen et al. 2002). In 
addition, to confirm diagnoses of prostate cancer, medical records were reviewed 
centrally by two study oncologists, and cancers with available histology or cytology 
(98%) were also reviewed by pathologists. 
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7.1.5 Other study variables 
Data on weight and height were based on measurements taken by specially trained 
study nurses, whereas most of the other variables used in this work were self-
reported. According to other population studies, self-reported smoking, for instance, 
is considered rather reliable (Patrick et al. 1994). The increasing social 
unacceptability of smoking could, however, have led to underreporting (Jarvis et al. 
1987). There is also considerable underestimation in the assessment of alcohol 
consumption in population surveys; in Finland, the population survey-based estimate 
accounts for only 40% of total alcohol consumption as measured by sales statistics 
(Simpura et al. 1995). Thus, the way in which data are collected must be kept in 
mind when interpreting the results. 
 
7.2 Serum enterolactone concentration and determinants 
7.2.1 Enterolactone concentrations 
Although a large range in serum enterolactone concentration was evident  
(0-183 nmol/l), 90% of subjects had a concentration under 38 nmol/l. Overall, the 
mean enterolactone concentration was of the same order of magnitude as previous 
reports in Finland (Uehara et al. 2000, Pietinen et al. 2001, Stattin et al. 2002, 
Vanharanta et al. 2002b, 2003). In the men, concentrations were higher than in 
Norwegian men (Stattin et al. 2002) but lower than in Japanese (Morton et al. 2002) 
or American (Morton et al. 1997a, 2002) men. The average serum enterolactone 
concentrations of women were slightly higher than concentrations observed in 
Japanese (Uehara et al. 2000) and Italian women (Albertazzi et al. 1999) and 
comparable with  those previously measured in American (Zeleniuch-Jacquotte et al. 
1998) and Swedish women (Hulten et al. 2002). Due to differences in study 
populations, sample sizes, and methods of analysis between these studies, further 
investigations in representative populations are needed for reliable comparisons. 
7.2.2 Determinants 
The number of antimicrobial purchases and self-reported constipation were the most 
important predictors of serum enterolactone concentration. In addition, consumption 
of fruit and berries and time from last antimicrobial treatment were positively 
associated with serum enterolactone concentrations in men, whereas in women 
concentrations were positively associated with age and consumption of vegetables, 
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and negatively associated with smoking and BMI. However, these variables 
explained only a small part of the variation in serum enterolactone concentration. 
The traditional Finnish diet is believed to be richer in lignans than typical Western 
diets because of relatively high intake of whole-grain products, particularly rye 
bread, and berries. However, the mean daily intake of lignans in our population was 
very low, <0.2 mg. Current information on lignan intake in other populations is 
limited, and comparisons of published reports are complicated by, for example, 
differences in the way food consumption data were collected and phytoestrogen 
databases were developed. Nevertheless, the mean daily intake of lignans in Finland 
appears to be comparable with, or even lower than, intakes in the United States, 
whereas the main sources of lignans were quite similar among both populations, i.e. 
grain products, vegetables, and fruit and berries (Strom et al. 1999, Horn-Ross et al. 
2000, 2001, 2002a, 2002b, 2003, de Kleijn et al. 2001, Walcott et al. 2002). 
Serum enterolactone concentration rather weakly reflected the actual intake of 
lignans, which can at least partly be explained by incompleteness of our database, 
e.g. recently discovered new precursors of enterolactone were missing. Serum 
enterolactone concentration had, however, a stronger association with the usual 
consumption of lignan-containing foods, i.e. fruit and berries in men and vegetables 
in women. In most previous studies, serum enterolactone concentration has been 
positively associated with consumption of vegetables (r=0.16-0.24, Adlercreutz et 
al. 1991, Horner et al. 2002, Vanharanta et al. 2002b, 2003), but no consistent 
association with consumption of fruit and berries (r=0.08-0.25) has been found 
(Horner et al. 2002, Vanharanta et al. 2003). 
Regarding other lifestyle factors, our findings support earlier observations that 
younger female subjects (Rowland et al. 1999, Horner et al. 2002), female smokers 
(Hulten et al. 2002), and women with high BMI (Horner et al. 2002, Hulten et al. 
2002, Vanharanta et al. 2003) have lower serum enterolactone concentration. There 
are no obvious reasons for these associations. However, enterolactone has been 
shown to passess through the preadipocyte’s cell membrane (Adlercreutz et al. 1993, 
Wang et al. 1994), which means that in subjects with high BMI enterolactone may 
be "diluted" due to rapid transport into the cells, resulting in lower serum levels. 
Moreover, although the self-reported consumption of lignan-containing foods was 
almost the same in normal-weight women as in their under- or overweight 
counterparts, overweight individuals may overestimated their consumption of these 
healthy products, a finding described previously (Hirvonen et al. 1997). The diet of 
smokers has also been shown to be more unhealthy from that of nonsmokers 
(Dallongeville et al. 1998, Birkett 1999); here, smokers consumed less whole-grain 
products, vegetables, and fruit and berries than nonsmokers. This may explain why 
smokers had lower serum enterolactone concentrations than nonsmokers. Moreover, 
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serum estrogen concentrations during oral hormone administration but not during 
percutaneous administration seem to be lower in postmenopausal smokers than in 
nonsmokers (Jensen et al. 1985, Jensen & Christiansen 1988), which implies that the 
effects of smoking on sex hormones occur during absorption or in hepatic 
metabolism of hormones. The structural similarity of enterolactone to estrogens may 
enable smoking to also affect the metabolism of enterolactone. Further, cigarette 
smoke increases oxidative stress (Frei et al. 1991) and, like all phenolic compounds, 
enterolactone is likely to have antioxidant properties (Prasad 1997, Kitts et al. 1999). 
Enterolactone might therefore be consumed to eliminate free radicals, leading to 
lower serum enterolactone concentrations in smokers than in non-smokers. 
Probably the most important factor affecting serum enterolactone concentration is 
the colonic environment. After ingestion, the precursors of enterolactone are 
metabolized by the action of the intestinal microflora (Borriello et al. 1985). The 
essential role of intestinal bacteria in the metabolism of mammalian lignans has 
previously been suggested by studies in germ-free rats (Bowey et al. 2003) and in 
ileostomy patients (Pettersson et al. 1996) as well as by a small-scale human study 
showing that oral administration of metronidazole or wide-spectrum oxytetracycline 
reduces urinary excretion of lignans (Setchell et al. 1981a). These results are 
supported by our findings that use of antimicrobials was inversely and in a dose-
dependent manner associated with serum enterolactone. However, the specific 
bacteria involved in the conversion of plant lignans to mammalian lignans have not 
been been fully identified. We observed the greatest suppression to be caused by 
macrolides, but the broad antibacterial spectrum of macrolides limits the speculation 
of the specific bacterial strains involved in the metabolism of lignans. 
The important role of the colonic environment and metabolism is also supported by 
our findings that subjects who had reported suffering from constipation had 
significantly higher serum enterolactone concentration than their symptomless peers. 
Subjects with constipation probably have slower intestinal motility, and thus, the 
metabolism and absorption of lignans may be more complete than in asymptomatic 
subjects. Moreover, subjects suffering from constipation may increase their 
consumption of foods rich in fiber to prevent symptoms of constipation. However, 
here, the consumption of lignan-containing foods was the same in both 
asymptomatic and symptomatic subjects. 
In summary, the hypothesis that serum enterolactone concentration is determined 
not only by intake levels but also by action of microflora is strongly supported by 
our findings. Moreover, the modest proportion of serum enterolactone concentration 
explained by the determinants examined here suggests the existence of other, still 
unknown, determinants. 
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7.3 Serum enterolactone concentration and risk of cancers  
7.3.1 Breast cancer 
The results of the nested case-control study (IV) do not support the hypothesis that 
high serum enterolactone concentration is associated with reduced risk of breast 
cancer. Overall, our findings are in accord with those of previous prospective studies 
where risk of breast cancer has not been associated with urinary enterolactone 
excretion (den Tonkelaar et al. 2001) and has only shown a marginal inverse 
association with serum enterolactone concentration (Hulten et al. 2002). Contrary to 
these findings, in three case-control studies, risk reductions between high and low 
serum (Pietinen et al. 2001) or urinary (Ingram et al. 1997, Dai et al. 2002) 
enterolactone concentration have been approximately 60%. Similar results have also 
been obtained in studies where intake of lignans was the focus: no association 
between intake of lignans and breast cancer risk was observed in prospective studies 
(Horn-Ross et al. 2001, 2002b, Keinan-Boker et al. 2004), while in case-control 
studies intake of mammalian lignans were inversely associated with risk of breast 
cancer, mostly in premenopausal women (McCann et al. 2002, Linseisen et al. 
2004). In case-control studies, because enterolactone concentrations and intake of 
lignans have been assessed after breast cancer occurrence, causal interpretation of 
the results is seriously limited.  
One potential source of bias in the present study is the lack of information on 
participants’ reproductive histories and other risk factors. However, in previous 
studies, adjustment for these factors has not affected results substantially (den 
Tonkelaar et al. 2001, Horn-Ross et al. 2001, Pietinen et al. 2001, McCann et al. 
2002). Thus, lack of this information is unlikely to have affected our results 
considerably. Another potential limitation is the absence of information on antibiotic 
use by study participants. We have no reason to assume, however, that use of 
antimicrobials differed between cases and controls. Finally, this study was limited 
by the range of enterolactone exposure (interquartile range 9-32 nmol/l) and 
concentrations being low compared with values observed to have beneficial effects 
in experimental studies. 
7.3.2 Prostate cancer 
The results of the case-control study (V) nested within a trial-based cohort of more 
than 29 000 Finnish men do not support the hypothesis that high levels of circulating 
enterolactone are associated with reduced risk of prostate cancer. Our findings are in 
agreement with the only published epidemiological study on circulating 
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enterolactone and prostate cancer (Stattin et al. 2002). In this nested case-control 
study based on population cohorts from Finland, Sweden, and Norway, no 
significant association between serum enterolactone and risk of prostate cancer was 
found (OR for the highest quartile 1.08, 95% CI 0.83-1.39). Moreover, no 
relationship between dietary intake of lignans and prostate cancer was observed in a 
case-control study conducted in the United States (Strom et al. 1999). 
Men in our study were aged 50-69 years at blood collection, and among men in this 
age bracket an occult malignancy of the prostate has been observed to occur at high 
frequencies (Pienta & Esper 1993). In fact, 67% of cases and 10% of controls had a 
baseline PSA level >4 ng/ml, which is associated with a >20% risk of prostate 
cancer (Stenman et al. 1999). Exclusion of these subjects from the analyses did not, 
however, produce substantially different results. Nor did restriction of analyses to 
subjects with at least two years of prostate cancer-free follow-up alter the 
enterolactone-prostate cancer association. Therefore, the lack of inverse association 
between serum enterolactone and prostate cancer cannot be due to a high prevalence 
of subclinical prostate cancers at baseline. 
Trial supplementation did not modify the serum enterolactone-prostate cancer 
association. Smoking, however, has been associated with a greater risk of fatal 
prostate cancer (Hsing et al. 1990, 1991), and tobacco may increase the virulence of 
tumors (Visakorpi et al. 1992). Because the ATBC study did not include 
nonsmokers, we cannot directly evaluate whether smoking modified the serum 
enterolactone-prostate cancer association. Although serum enterolactone 
concentration correlated negatively with the number of cigarettes smoked per day 
and positively with the number of smoking years in the ATBC study controls, the 
mean enterolactone levels in this study were comparable with other reports (Uehara 
et al. 2000, Stattin et al. 2002, Vanharanta et al. 2002b, 2003). It should also be 
noted that while information on use of antimicrobials was unavailable in this study 
there is no reason to assume that use differed between cases and controls. Finally, in 
our population, the exposure range was limited (interquartile range 6-24 nmol/l) and 
serum enterolactone concentrations were rather low compared with values shown to 
be beneficial in experimental studies. 
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8 CONCLUSIONS 
Based on the main findings, the following conclusions were drawn: 
 
1. The range in serum enterolactone concentration among the Finnish population 
was large (0-183 nmol/l), but 90% of subjects had a concentration under  
38 nmol/l. 
2. Lignans, especially secoisolariciresinol, were common components of the 
Finnish diet, but the mean daily lignan intake, <0.2 mg, was much lower than 
doses shown to be beneficial in experimental studies. Serum enterolactone 
concentration rather weakly reflected recent intake of lignans but more 
strongly the consumption of lignan-containing foods, i.e. fruit and berries and 
vegetables. 
3. Serum enterolactone concentration had a positive association with self-
reported constipation in both genders. In addition, it was positively associated 
with age and negatively associated with smoking and BMI in women. The 
modest proportion of serum enterolactone concentration explained by the 
variables examined suggests the existence of other, still unknown, 
determinants. 
4. Serum enterolactone concentration was negatively associated with the 
number of antimicrobial treatments in both genders. In addition, it had a 
positive association with the length of time from last antimicrobial treatment 
in men. These findings support the central role of gut microflora in the 
bioavailability of lignans. 
5. Serum enterolactone concentration was not protectively associated with risk 
of breast or prostate cancers. 
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9 FUTURE DIRECTIONS 
Large gaps remain in the knowledge of lignans and their impact on human health. 
The following topics should be considered for future research:   
 
1. The metabolism of lignans is still poorly understood, and therefore, studies on 
lignan bioavailability and stability in plasma, their distribution in the human 
body, and their concentrations in different tissues are needed. 
2. The normal ranges of serum enterolactone concentration in different 
populations should be studied in large representative population samples.  
3. Uncovering new determinants of serum enterolactone concentration requires 
further studies. This also includes updating lignan databases to include new 
enterolactone precursors. 
4. Limited understanding of biological effects and mechanisms of action of 
enterolactone warrant more experimental studies, especially at concentrations 
of enterolactone commonly measured in populations. This should also include 
dose-response studies to clarify the concentration needed to achieve the 
desired effect. 
5. More prospective epidemiological studies are required to clarify the 
association between serum enterolactone concentration and risk of hormone-
dependent cancers and other chronic diseases.  
6. If convincing evidence of the association between high lignan exposure and 
reduced risk of chronic diseases is obtained, clinical trials in humans are 
warranted to establish the beneficial effects of lignans on these diseases. 
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